INCR: InterCure Ltd Earnings per share for the last twelve months

InterCure Ltd. (INCR) is positioned for growth due to its status as the undisputed favorite in the Israeli medical cannabis sector. This potential is based on expanding pharmacy coverage in Germany and Israel under strict GMP control. The TTM annual earnings per share confirms the trend, with the current level sitting around -1.00. Cost optimization through external logistics and outsourced marketing helps the company adapt flexibly to regulatory changes.

INCR (InterCure Ltd.) Net earnings per share for the last four quarters history from 07/04/2022 to 11/15/2026

Canndoc (INCR) - metric breakdowns and financial figures

- current quotes and average value forecast:

Price Chart InterCure|INCR - Fair Value Consensus

- market capitalization information:

Market Value INCR|INCR - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Book Value per Share InterCure|INCR - Book Valuation of Business|Market Value to Book Value Ratio intercure.co|INCR - Total Business Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

INCR - Net Profit|Expected Profit InterCure Ltd.|INCR - Company Value to Net Income|Forward P/E Multiple Canndoc|INCR - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio INCR|INCR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months InterCure|INCR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months intercure.co|INCR - Net earnings per one share growth for the current year|Earnings growth forecast for next year InterCure Ltd.

- total revenue and sales volume data:

INCR - Company Sales Volume|Company Future Sales Volume InterCure Ltd|INCR - Price-to-Revenue Coefficient|Forward P/S Multiple InterCure

Basic company analysis:INCR - Canndoc

Conservative capital demands absolute transparency regarding the business's actual earnings per share. This indicator aggregates net income over a rolling year, excluding short-term fluctuations to assess margin sustainability. For InterCure Ltd. (INCR), this is critical, as regulatory compliance costs limit the effects of production scaling. The investor sees the real efficiency of capital net of operating expenses. The current trailing 12-month EPS value objectifies this trend.

Competing companies